title: Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
abstract: To characterize and evaluate human serum albumin-encapsulated nanoparticles for drug delivery of a tyrosine kinase inhibitor combined with induction of photothermal ablation combination therapy of renal cell carcinoma (RCC), nanoparticles of varying preparations and concentrations were characterized via zeta potential, drug loading, and release profile. Cytotoxicity and uptake trials were also studied using clear cell RCC cell line RCC 786-0, a human metastatic carcinoma. Target temperatures of >50°C were consistently attained by 0.1 and 0.05 μM concentrations of irradiated human serum albumin nanoparticle-gold nanorods (HSAP-AuNRs). Irradiated trials of HSAP-AuNRs demonstrated significantly decreased cell viabilities compared with nonirradiated "dark" controls (p < 0.01). Increasing loaded masses of sorafenib (SRF) also significantly decreased relative cell viability of RCC (p < 0.05). Photothermal ablation using HSAP-AuNRs is capable of inducing significant hyperthermia while the loading of SRF further enhances cytotoxicity relative to treatment with HSAP-AuNRs alone. HSAP-AuNR-SRFs have the potential to be an effective, novel combination treatment for advanced RCC.
authors: Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana 70112.
authors: Cameron
authors: C
authors: Callaghan
authors: Department of Chemistry and Advanced Materials Research Institute, University of New Orleans, New Orleans, Louisiana 70148.
authors: Donna
authors: D
authors: Peralta
authors: Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana 70112.
authors: James
authors: J
authors: Liu
authors: Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana 70112.
authors: Sree Harsha
authors: SH
authors: Mandava
authors: Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana 70112.
authors: Michael
authors: M
authors: Maddox
authors: Department of Pathology, Tulane University School of Medicine, New Orleans, Louisiana 70112.
authors: Srikanta
authors: S
authors: Dash
authors: Department of Chemistry and Advanced Materials Research Institute, University of New Orleans, New Orleans, Louisiana 70148.
authors: Matthew A
authors: MA
authors: Tarr
authors: Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana 70112. Electronic address: brlee@tulane.edu.
authors: Benjamin R
authors: BR
authors: Lee
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D003374:Coumarins / Q000737:chemistry; D004339:Drug Compounding; D006046:Gold; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D007834:Lasers; D043942:Nanotubes; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D012709:Serum Albumin / Q000737:chemistry; D012995:Solubility; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D003374:Coumarins; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D012709:Serum Albumin; D009536:Niacinamide; D006046:Gold; D000077157:Sorafenib; C030123:coumarin; D011505:Protein-Tyrosine Kinases
keywords: gold nanorods; microencapsulation; nanotechnology; photothermal ablation; renal cell carcinoma; sorafenib